Drug Retail

YIXINTANG

YIXINTANG released FY2025 Annual Earnings on April 28 (BJT), actual revenue CNY 17.34 B (forecast CNY 17.34 B), actual EPS CNY 0.4571 (forecast CNY 0.5301)

YIXINTANG released FY2025 Q4 earnings on April 28, 2026 (BJT), actual revenue CNY 4.335 B (forecast CNY 4.37 B), actual EPS CNY -0.0094 (forecast CNY 0.0014)

YIXINTANG released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 4.434 B (forecast CNY 4.283 B), actual EPS CNY 0.3002 (forecast CNY 0.2074)

YIXINTANG to Release FY2026 Q1 Earnings on April 29 After-Market BJT, Forecast Revenue CNY 4.283 B, EPS CNY 0.2074

YIXINTANG to Release FY2025 Annual Earnings on April 29, 2026 (BJT), Forecast Revenue CNY 17.34 B, EPS CNY 0.5301

YIXINTANG released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 13 B, actual EPS CNY 0.4586

YIXINTANG released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 4.087 B (forecast CNY 4.406 B), actual EPS CNY 0.0323 (forecast CNY 0.13)

YIXINTANG to release FY2025 Q3 earnings on October 31 After-Market BJT, forecast revenue CNY 4.406 B, EPS CNY 0.13

YIXINTANG released FY2025 Semi-Annual Earnings on August 29 Pre-Market (BJT), actual revenue CNY 8.914 B, actual EPS CNY 0.4263

YIXINTANG released FY2025 Q2 earnings on August 29 Pre-Market (BJT), actual revenue CNY 4.148 B (forecast CNY 4.516 B), actual EPS CNY 0.1529 (forecast CNY 0.2422)

YIXINTANG to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Yixin Tang Holds Site Visit to Discuss Store Transformation Strategies

Yixin Tang Topped Limit Up, Institutions Net Buy

Yixin Tang Management Answers Investor Questions on Performance and Debt

Investors Suggest Yixintang Strengthen Online Sales and Pet Market Strategy

Yixin Tang Announces Q1 2025 Earnings: Revenue Down 6.53%, Net Profit Down 33.83%

YIXINTANG released FY2024 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 4.411 B (forecast CNY 4.579 B), actual EPS CNY -0.3068 (forecast CNY 0.3745)

YIXINTANG released FY2024 earnings on April 27 After-Market BJT, actual revenue CNY 18 B (forecast CNY 18.44 B), actual EPS CNY 0.1927 (forecast CNY 1.0671)

YIXINTANG released FY2025 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 4.767 B (forecast CNY 5.212 B), actual EPS CNY 0.2733 (forecast CNY 0.3475)

YIXINTANG to release FY2025 Q1 earnings on April 28 After-Market (BJT), forecast revenue CNY 5.212 B, EPS CNY 0.3475

01833

510660

589720

603939

603883

605266

159929

002727

36Kr learned that recently, after Ping An Good Doctor reached deep cooperation with two major listed chain pharmacies, LBX and Yifeng, the "Ping An Circle" offline service network has achieved significant implementation in the southwest market: "Ping An Circle" successfully signed deep cooperation agreements with three regional chains, YIXINTANG, JZJ, and Guizhou Yishu

36Kr

PA GOODDOCTOR

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

Yifeng Pharmacy

China Universal 800 Health Care ETF

The "Ping An Circle" has signed a deep cooperation agreement with YIXINTANG, JZJ, and Guizhou Yishu, three major regional chains

512010

601607

600511

159938

603233

000028

Recently, the policy dividends in the pharmaceutical retail industry have been continuously released, and the pace of transformation and integration upgrades has accelerated. The Ministry of Commerce and eight other departments jointly issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry," introducing support measures to promote the transformation and upgrading of the industry. Industry insiders stated that policy guidance, market clearing, and model innovation are advancing simultaneously, and the pharmaceutical retail industry has entered a new stage of structural optimization and increased concentration, with leading enterprises that have scale advantages set to benefit significantly

Wallstreetcn

E Fund CSI 300 Health Care ETF

Shanghai Pharma

SINOPHARM(CNCM LTD)

GF CSI All Share Health Care ETF

Sinopharm Accord

Policy dividends continue to be released, and the pharmaceutical retail industry welcomes new opportunities for transformation

According to the Zhitong Finance APP, YIXINTANG released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 13 billion yuan, a year-on-year decrease of 4.33%. The net profit attributable to shareholders of the listed company was 269 million yuan, a year-on-year decrease of 8.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 253 million yuan, a year-on-year decrease of 26.27%

Zhitong

YIXINTANG released its performance for the first three quarters, with a net profit attributable to the parent company of 269 million yuan, a year-on-year decrease of 8.17%

600000

YIXINTANG Pharmaceutical Group Co., Ltd. recently signed a "Maximum Guarantee Contract" with the Chengdu Branch of SPD Bank, providing a joint liability guarantee of 20 million yuan for its holding subsidiary Sichuan Bencao Tang Pharmaceutical Co., Ltd. This guarantee is within the comprehensive credit guarantee limit of 1.368 billion yuan approved by the company's shareholders' meeting, and Sichuan Bencao Tang has a good credit rating with controllable risks. After the guarantee, the company's and its holding subsidiaries' guarantee limit reaches 1,282.27 million yuan, accounting for 7.60% of the net assets in 2024

SPD Bank

YIXINTANG provides a guarantee of 20 million for its holding subsidiary Sichuan Bencao Tang

CITIC Construction Investment released a research report indicating that the pharmacy industry is experiencing a mild recovery, while traditional pharmacies face development pain points, making differentiated transformation imperative. The industry needs to adapt to the economic environment, policy changes, and consumer habits, differentiating into specialized and diversified pharmacies. Specialized pharmacies meet the needs of patients discharged from hospitals, while diversified pharmacies focus on daily health needs. Compared to Japan, pharmacy companies need to leverage policy support to promote differentiated development in order to gain additional growth

CITIC Construction Investment: The pharmacy industry is currently recovering moderately, and transformation is expected to catalyze valuation enhancement

YIXINTANG released its 2025 semi-annual report, with operating revenue of 8.914 billion yuan, a year-on-year decrease of 4.20%; net profit attributable to the parent company was 250 million yuan, a year-on-year decline of 11.44%; net profit excluding non-recurring gains and losses was 243 million yuan, a year-on-year decrease of 18.41%. Basic earnings per share were 0.4263 yuan, and it plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders

YIXINTANG released its performance for the first half of the year, with a net profit attributable to the parent company of 250 million yuan, a decrease of 11.44%

301017

China Post Securities released a research report indicating that the retail pharmacy industry is accelerating its clearance, with the number of closed pharmacies reaching 39,228 in 2024. It is expected that after industry consolidation, leading pharmacies will see a recovery in customer traffic. Leading pharmacies, leveraging their first-mover advantage in outpatient management, will attract more customers, enhance medical insurance consumption and related product consumption, thereby increasing the average transaction value and performance. Policy-driven prescription outflow and the trend of incorporating retail pharmacies into medical insurance management will further promote industry development

SYPM

China Post Securities: The retail pharmacy industry continues to clear out, and the ongoing coordination is expected to bring performance growth

According to the Qichacha APP, recently, YIXINTANG Handmade Yunnan Catering Co., Ltd. was established, with Yang Meng as the legal representative. The business scope includes enterprise management; brand management; marketing planning; supply chain management services; and organizing cultural and artistic exchange activities, among others. Qichacha's equity penetration shows that the company is jointly held by YIXINTANG's wholly-owned subsidiary Yunnan Hongxiang Traditional Chinese Medicine Technology Co., Ltd. and others

Yinhua CSI Chinese Medicine ETF

YIXINTANG and others establish a new catering company in Yunnan

The pharmacy sector saw a short-term surge, with YIXINTANG hitting the limit up, while Shuyu Pingmin, Jianzhijia, Huaren Health, First Pharmaceutical, and Yifeng Pharmacy all rose significantly

Huaren Health

NO.1 PHARMACY

The pharmacy sector sees a short-term surge, YIXINTANG hits the limit up

YIXINTANG(002727.SZ)